Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy symbols : Mrk save search
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.32%
H: 0.42%
C: 0.26%
keytruda advanced therapy
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
Published: 2023-11-01 (Crawled : 11:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.83%
H: 0.66%
C: -0.68%
keytruda renal cell therapy
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
Published: 2023-03-27 (Crawled : 23:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 1.22%
H: 1.44%
C: 0.8%
keytruda plus therapy
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Published: 2023-03-06 (Crawled : 21:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 3.2%
hypertension week therapy
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.23%
H: 0.55%
C: -0.27%
keytruda plus therapy
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Published: 2023-01-25 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.11%
ynote-991 keytruda trial plus therapy cancer prostate cancer
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.31%
H: 0.12%
C: -0.75%
mk-2060 fda designation therapy fast track designation
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -1.53%
H: 0.93%
C: -0.83%
keytruda fda application therapy cancer
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Published: 2022-04-14 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
fda disease granted therapy pneumococcal
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.04%
H: 1.56%
C: 1.01%
keytruda disease cel lung cancer therapy cancer
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.5%
H: 1.66%
C: 0.93%
ynote-716 keytruda trial therapy phase 3
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Published: 2022-01-27 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.91%
H: 4.05%
C: 2.75%
keytruda europe renal cel therapy cell carcinoma
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Published: 2021-12-27 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.36%
H: 0.8%
C: 0.75%
keytruda trial therapy cancer
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
Published: 2021-12-17 (Crawled : 14:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
keytruda renal cel positive therapy chmp cell carcinoma
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Published: 2021-11-30 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
treatment keytruda therapy
Health Canada Approves KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1
Published: 2021-11-23 (Crawled : 18:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
treatment keytruda therapy cancer breast cancer
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Published: 2021-11-18 (Crawled : 13:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -2.35%
H: 1.01%
C: 0.91%
keytruda fda renal therapy fda approval cell carcinoma
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
Published: 2021-10-22 (Crawled : 11:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
treatment europe therapy cancer breast cancer keytruda
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Published: 2021-09-20 (Crawled : 17:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -1.74%
H: 2.9%
C: 1.87%
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.14%
H: 2.04%
C: 1.08%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.18%
H: 1.22%
C: -0.23%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.52%
H: 9.63%
C: 3.06%
space cancer spac therapy
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
Published: 2021-09-17 (Crawled : 13:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
positive therapy cancer breast cancer chmp keytruda
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.